Phase 4 Study of Response to EGFR-TKI and Correlation With C-met Expression and EGFR Gene Mutation in NSCLC Patients Treated With Erlotinib
Observational
Observational Model: Case-Only, Time Perspective: Prospective
The rates of C-met expression/amplification and EGFR gene mutations
To investigate C-met expression/amplification and EGFR gene mutations in NSCLC patients treated with Erlotinib : C-met expression by IHC C-met amplification by SISH EGFR mutation by real time PCR
Average of 1 year
No
Young-Chul Kim, MD, PhD
Principal Investigator
Chonnam National University Hospital
South Korea: Korea Food and Drug Administration (KFDA)
MENTOR_2011
NCT01523340
December 2011
December 2015
Name | Location |
---|